(Q34254837)

English

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer (English)

1 reference

Europe PubMed Central

31 July 2017

0 references

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

James Lewis Abbruzzese

5

object named as

James L Abbruzzese

1 reference

Europe PubMed Central

31 July 2017

6

object named as

Donghui Li

1 reference

Europe PubMed Central

31 July 2017

2

object named as

Milind Javle

1 reference

Europe PubMed Central

31 July 2017

Motofumi Tanaka

1

object named as

Motofumi Tanaka

1 reference

Europe PubMed Central

31 July 2017

3

object named as

Xiaoqun Dong

1 reference

Europe PubMed Central

31 July 2017

4

object named as

Cathy Eng

1 reference

Europe PubMed Central

31 July 2017

language of work or name

0 references

publication date

1 November 2010

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

116

1 reference

Europe PubMed Central

31 July 2017

22

1 reference

Europe PubMed Central

31 July 2017

5325-5335

1 reference

Europe PubMed Central

31 July 2017

Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

A "silent" polymorphism in the MDR1 gene changes substrate specificity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Cellular pharmacology of gemcitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Assessing the probability that a positive report is false: an approach for molecular epidemiology studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Ribonucleotide reductase subunit one as gene therapy target: commentary re: M-Y. Cao et al., Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin. Cancer Res., 9: 4304-4308, 2003.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

28 October 2018

Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

28 October 2018

Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

28 October 2018

Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase

1 reference

https://pubmed.ncbi.nlm.nih.gov/20665488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism

1 reference

https://pubmed.ncbi.nlm.nih.gov/20665488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1)

1 reference

https://pubmed.ncbi.nlm.nih.gov/20665488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism

1 reference

https://pubmed.ncbi.nlm.nih.gov/20665488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20665488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics

1 reference

https://pubmed.ncbi.nlm.nih.gov/20665488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.25282

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34254837&oldid=1967316135"